Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 11,099

Document Document Title
WO/2018/224560A1
The present invention concerns a compound having the following formula (I): wherein: - A is in particular -N(R'a)-C(=O)-R, R'a being H or a (C1-C6)alkyl group, and R being preferably a group having the following formula (II): - X is in p...  
WO/2018/224563A1
The present invention concerns a compound having the following formula (I): wherein: - A is in particular -N(R'a)-C(=O)-R, R'a being H or a (C1-C6)alkyl group, and R being preferably a group having the following formula (II): - X is in p...  
WO/2018/215818A1
The present invention relates to compounds of formula (I): wherein Q is O or S; R1 is a cyclic group substituted with at least one group X, wherein R1 may optionally be further substituted; X is any group comprising a carbonyl group; and...  
WO/2018/215070A1
The present invention pertains to novel dual modulators of farnesoid X receptor (FXR) and soluble epoxide hydrolase (sEH). The modulators of the invention were designed to provide compounds which harbor a dual activity as agonists of FXR...  
WO/2018/215610A1
The present invention pertains to novel dual modulators of farnesoid X receptor (FXR) and soluble epoxide hydrolase (sEH). The modulators of the invention were designed to provide compounds which harbor a dual activity as agonists of FXR...  
WO/2018/215287A1
The invention relates to a color developer of formula (I), (Ar1-SO2-NH-)m-Y-(-NH-C(O)-NH-SO2-Ar2)n (I), wherein Ar1 is an unsubstituted or substituted aromatic moiety, Ar2 is an unsubstituted or substituted phenyl moiety, Y is at least a...  
WO/2018/213150A1
The application relates to phenyl- or naphthylsulfonamide derivatives of the structural formula (I). The compounds are described as inhibitors of USP30 (ubiquitin specific peptidase 30) useful for the treatment of conditions involving mi...  
WO/2018/212368A1
The present invention relates to a novel compound and a pharmaceutical composition, for preventing or treating degenerative neurological disorders, comprising the compound as an active ingredient. The novel compound, which is obtained by...  
WO/2018/210729A1
Substituted aromatic sulfonamides of formula (I), pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a d...  
WO/2018/212216A1
Provided is a method for producing an optically active isomer, the method including an asymmetry induction step in which an asymmetry-inducing agent is caused to act on chiral molecules having an enantiomeric-excess half-life period less...  
WO/2018/204987A1
Compounds are provided which are inhibitors of the CAXII enzyme. Due to the interaction between CAXII and Pgp, such compounds may be useful in lowering the chemoresistance of a cancer allowing for co-administration with existing anti-can...  
WO/2018/204775A1
A method for the treatment and/or reduction of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) is disclosed. The method uses active amino-aryl-benzamide compounds and methods for the preparation thereof.  
WO/2018/196677A1
The present invention relates to a fluoroallylamine derivative and the use thereof. In particular, the present invention relates to a compound as shown in formula I, a prodrug, an isomer, an isotopically labelled compound, a solvate or a...  
WO/2018/188795A1
The present invention relates to sulfonamide-, sulfinamide- or sulfonimidamide containing compounds which bind to the liver X receptor (LXRa and/or LXRß) and act preferably as inverse agonists of LXR.  
WO/2018/186040A1
Provided is an ionic liquid, characterized in containing a cationic component and an anionic component, and in that the cationic component comprises a group having a perfluoropolyether chain and a group having a hydroxyl group.  
WO/2018/181986A1
The present invention provides a pharmaceutical composition for treating or preventing cognitive function disease or disorder, the composition comprising a compound represented by formula (I), an enantiomer thereof, a diastereomer thereo...  
WO/2018/181884A1
The objective of the present invention is to provide a novel compound inhibiting the entry of a filovirus into a cell, a medical composition, an anti-filovirus agent, or a filovirus entry inhibitor containing the compound, as well as a m...  
WO/2018/179343A1
The present invention provides a pharmaceutical composition for treating or preventing cognitive function disease or disorder, the composition comprising a compound represented by formula (I), an enantiomer thereof, a diastereomer thereo...  
WO/2018/176134A1
The present disclosure relates to compounds for use as electrode additives or as salts in electrolyte compositions, and their methods of preparation. The majority of compounds are anions of imidazoles bearing a sulphonyl or a carbonyl gr...  
WO/2018/175682A1
The disclosure provides methods and compositions therefor for treating a surface wherein a surface treatment layer is formed on the surface, thereby minimizing or preventing pattern collapse as the surface is subjected to typical cleanin...  
WO/2018/169252A1
The present invention relates to an N-benzyl-N-phenoxyl carbonyl-phenyl sulfonamide derivative, which inhibits PGE2 generation by means of inhibiting microsomal prostaglandin E2 synthase-1 (mPGES-1) and has enhanced activity, a method fo...  
WO/2018/170306A1
The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions fu...  
WO/2018/161892A1
A benzene sulfonamide compound having structural features of formula (I) or a pharmaceutically acceptable salt thereof, a preparation method therefor, and use thereof as an indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor. Experimental res...  
WO/2018/159640A1
Provided are: a curable composition including a salt compound provided with a) an organic anion of which the values of the Hansen solubility parameters δd, δp, and δH are respectively 16 or higher, in the range of 16-32 inclusive, and...  
WO/2018/157240A1
The disclosure relates to a compound of formula: (I) Several different uses of this compound are described for preparing different compounds. For example, this compound makes it possible to graft a fluorosulfonyl group on a molecule. A m...  
WO/2018/159650A1
The purpose of the present invention is to provide a compound which has a guanidine skeleton and inhibits the protease activity of MALT1 to exhibit a therapeutic effect or prophylactic effect on autoimmune diseases such as psoriasis. The...  
WO/2018/156297A1
The present invention related to novel sulfonamides or amides as TLR-4 antagonists, and pharmaceutical formulations containing the same and the methods of use thereof. Uses of the present novel sulfonamides or amides include, but are not...  
WO/2018/154519A1
The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compo...  
WO/2018/145620A1
Potent 5-HT2B antagonist of Formula (A), including stereochemically isomeric forms, and salts, hydrates, solvates thereof and their use wherein R1 to R4 and Ar have the meaning as defined herein. The present invention also relates to pro...  
WO/2018/145874A1
The invention relates to a compound of the formula (I) Ar(NHSO2Ar1)l(SO2NHAr1)m(NHC(O)NHAr2)n (I), wherein l and m independently of one another are 0, 1, 2, 3, and/or 4 and the sum of l+m is equal to or more than 1, n is 2, 3, 4, or 5, A...  
WO/2018/130625A1
The present invention relates to novel substituted benzene disulfonamides, as well as pharmaceutical compositions containing at least one of these substituted benzene disulfonamides together with at least one pharmaceutically acceptable ...  
WO/2018/129556A1
The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-sta...  
WO/2018/128720A1
Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.  
WO/2018/117467A1
Disclosed in the specification is a method which selectively separates an R type enantiomer contained in a racemate (R/S=1/1) of N-[4-(1-amino-ethyl)-2,6-difluoro-phenyl]-methanesulfonamide , and then can convert the same back into the r...  
WO/2018/118827A1
The present invention is directed to compounds of Formula I, pharmaceutical compositions comprising the same, and their use in the inhibition of HIV protease, the inhibition of HIV replication, the prophylaxis of infection by HIV, the tr...  
WO/2018/107289A1
Compounds described herein are inhibitors of retinoic acid inducible P450 (CYP26) enzymes, and are useful for treating diseases that are responsive to retinoids. Certain compounds have retinoid activity, are resistant to CYP26-mediated c...  
WO/2018/104307A1
Substituted aromatic sulfonamides of formula (I), pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a d...  
WO/2018/104305A1
Substituted aromatic sulfonamides of formula (I) which are antagonists or negative allosteric modulators of P2X4, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing a ph...  
WO/2018/103583A1
Inhibitors with anti-inflammatory agents are provided, as are methods of using the analogs to inhibit inflammation and prevent or treat diseases and conditions associated with inflammation, such as multiple sclerosis and autoinflammatory...  
WO/2018/102419A1
The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.  
WO/2018/095488A1
The invention relates to sulfobetaine compounds, a process for synthesizing same, and the uses of sulfobetaine compounds for synthesizing antimicrobial materials, antistatic materials, antifouling materials, printing inks, surface-active...  
WO/2018/098209A1
Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.  
WO/2018/093694A1
Disclosed are compounds of Formula A, or a salt thereof: Formula (A), wherein: Het, Q and R1A to R4A are defined herein, which compounds have properties for blocking Nav 1.7 ion channels found in peripheral and sympathetic neurons. Also ...  
WO/2018/086531A1
Disclosed are a series of sulfonamides compounds, represented by general formulas (I) and (II), serving as cccDNA inhibitors, and tautomers or pharmacologically acceptable salts thereof.  
WO/2018/086507A1
The invention discloses a naphthalene sulfonamide type compound, a preparation method thereof and an application thereof for regulating plant growth activity. A general formula of a structure of the naphthalene sulfonamide type compound ...  
WO/2018/085171A1
The present disclosure relates to compounds of formula (I) that are useful as modulators of α7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly ...  
WO/2018/085170A1
The present disclosure relates to compounds of formula (I) that are useful as modulators of α7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly ...  
WO/2018/078657A1
The present invention discloses a simple, economic, consistent, commercially viable and industrially applicable process for preparation of Glipizide in high yield and highly pure Glipizide having purity more than 95%, preferably more tha...  
WO/2018/072024A1
The invention relates to methods for the production of sulphamic acid derivatives, for example, halogenated derivatives and the salts thereof, metallic or organic, are described. The present application also relates to the resulting sulp...  
WO/2018/068295A1
Substituted aryl and heteroaryl ether compounds of the Formula (I) and pharmaceutically acceptable salts thereof, wherein X, R 1, R 2, R 3, L, R 4, L 1, Q, and R 5 are as defined herein. These compounds and pharmaceutically acceptable co...  

Matches 1 - 50 out of 11,099